Article
Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?
Current pharmaceutical design - 1 Jan 2013
Kassimis George, Stavrou Eleana F, Alexopoulos Dimitrios, Athanassiadou Aglaia
Abstract excerpt
CYP2C19 is one of the principal enzymes involved in the metabolism of clopidogrel. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function. A loss-of-function allele, CYP2C19*2, is associated with an increased risk of major adverse cardiovascular events, particularly stent thrombosis, in patients with acute coronary syndromes who are receiving clopidogrel, especially among...
Topics
Join the communities discussing this publication.